Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 189, 105063
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
This publication has 47 references indexed in Scilit:
- The Cellular Ataxia Telangiectasia-Mutated Kinase Promotes Epstein-Barr Virus Lytic Reactivation in Response to Multiple Different Types of Lytic Reactivation-Inducing StimuliJournal of Virology, 2012
- BZLF1 Governs CpG-Methylated Chromatin of Epstein-Barr Virus Reversing Epigenetic RepressionPLOS Pathogens, 2012
- Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1in tumors of epithelial, NK- and B-cell originsBMC Cancer, 2012
- PRDM1 is a tumor suppressor gene in natural killer cell malignanciesProceedings of the National Academy of Sciences, 2011
- The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapyTherapeutic Advances in Medical Oncology, 2011
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- A Novel KRAB Domain-containing Zinc Finger Transcription Factor ZNF431 Directly Represses Patched1 TranscriptionJournal of Biological Chemistry, 2011
- Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportHaematologica, 2009
- TORC2, a Coactivator of cAMP-response Element-binding Protein, Promotes Epstein-Barr Virus Reactivation from Latency through Interaction with Viral BZLF1 ProteinJournal of Biological Chemistry, 2009
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000